Rochelle Bagatell, MD, is a pediatric oncologist with expertise in the care of children with solid tumors. She has a particular interest in the treatment of patients with sarcomas and neuroblastoma, and co-directs the solid tumor program at The Children's Hospital of Philadelphia.
Current treatment regimens are effective for many children diagnosed with solid tumors in childhood, and the collaborative approach taken at Children's Hospital allows patients to benefit from the expertise of surgeons, pathologists, radiologists, radiation oncologists, nurses, nutritionists and other specialists who work together to provide state-of-the-art care for patients. The solid tumor team is committed to optimizing the effectiveness of current therapies while trying to minimize the side effects of treatment.
This group is also committed to developing new treatments for childhood solid tumors. As a member of Children's Hospital’s oncology developmental therapeutics team, Dr. Bagatell is involved in research studies (clinical trials) of new agents for patients whose cancers don't respond to initial or established treatments. She and colleagues conduct research trials that provide patients access to the newest anticancer medications. The team studies novel treatments that haven't previously been administered to children. These trials permit better understanding of how to use new treatments in the most effective way. The team is currently expanding the number of new agent trials available to patients, and collaborates with colleagues from around the region and nation in efforts to advance the field.
While there are tremendous challenges inherent in the pursuit of new treatments, the solid tumor and developmental therapeutics teams have the opportunity to build upon the expertise at Children’s Hospital to develop newer, less toxic treatments for childhood cancer. Dr. Bagatell’s highest priority is to make innovative treatments available to the children who need them.
- Education and Training
MD - University of Arizona, Tucson, AZ
Pediatrics - University of Arizona, Tucson, AZ
Pediatrics - University of Arizona, Tucson, AZ
Pediatric Hematology/Oncology - Children's Memorial Hospital, Northwestern University, Chicago, IL
Pediatric Hematology/Oncology - University of Arizona, Tucson, AZ
- Titles and Academic Titles
Solid Tumor Section Chief
Medical Director for Oncology, International Patient Services
Associate Professor, Perelman School of Medicine at the University of Pennsylvania
- Departments and Services
- Research Interests
Brodeur GM, Hogarty MD, Mosse YP, Bagatell R and Maris JM. Neuroblastoma. Chapter 30. Principles and Practice of Pediatric Oncology Seventh Edition. Pizzo P and Poplack D, Eds., In press.
Adamson P, Bagatell R, Balis FM, Blaney SM. General Principles of Chemotherapy. Chapter 10, Principles and Practice of Pediatric Oncology Seventh Edition, Pizzo P and Poplack D, Eds., In press.
Hawkins DS, Leary S, Bagatell R, Merchant M, Aerts I. Solid Tumors. Chapter 11, Hematopoietic Cell Transplantation in Children with Cancer. Smith F, Reaman GH, Racadio JM, Eds. Pages 303-349, 2014.
Parikh S, Bagatell R. Bone tumors. In: Florin TA, Ludwig S, editors. Netter's pediatrics. Philadelphia: Saunders Elsevier; 2011. Ch. 60, p. 366-71.
Bagatell R, Park J. Neuroblastoma. In: Lanzkowsky P, editor. Handbook of pediatric hematology and oncology. 5th ed. London, UK: Academic Press; 2011. Ch. 22, p. 671.
Adamson P, Bagatell R, Balis FM, Blaney SM. In: Pizzo PA, Adamson PC, Poplack DG (eds). Principles and Practice of Pediatric Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins. 2010.
Meany HJ, Dome J, Hinds PS, Bagatell R, Shusterman S, Widemann BC, Stern E, London WB, Kim A, Fox E, Rodriguez-Galindo C, Minturn JE. Phase 1 Study of Sorafenib and Irinotecan in Pediatric Patients with Relapsed or Refractory Solid Tumors. American Society of Clinical Oncology Annual Meeting, Chicago, June 2014.
London WB, Bagatell R, Weigel B, Fox E, Van Ryn C, Naranjo A, Krailo MD, Ahern CH, Park JR. Historical Gold Standard for Time-to-Progression (TTP) and Progression-Free Survival (PFS) from Relapsed/Refractory Neuroblastoma Modern Era (2002-2014) Patients. American Society of Clinical Oncology Annual Meeting, Chicago, June 2014.
Aplenc R, Fisher B, Li Y, Alonzo TA, Gerbing RB, Hall M, Arnold SD, Huang Y-S, Seif AE, Bagatell R, Sung L, Adamson PC, Gamis AS, Keren R. Standardized Costs and Outcome in Children Treated with Gemtuzumab on the AAML0531 Trial: A Report from the Children’s Oncology Group. American Society of Clinical Oncology Annual Meeting, Chicago, June 2014.
Goodman EK, Reilly AF, Li Y, Seif AE, Fitzgerald J, Huang Y-S, Bagatell R, Fisher B, Aplenc R. Impact of Weekend Admission on Hospital Length of Stay and Organ Failure in Pediatric Leukemia Patients at Free-Standing US Children’s Hospitals. American Society of Clinical Oncology Annual Meeting, Chicago, June 2014.
Batra V, Miller A, States LJ, Bhatia A, Li Y, Maris J, Bagatell R. Response is Soft Tissue Lesions Following Therapeutic 131I MIBG in Children with Neuroblastoma. Advances in Neuroblastoma Research, Cologne, April 2014. Bagatell R, Fisher B, Seif AE, Huang Y-S, Li Y, Desai A, London W, Van Ryn C, Park JR, Richardson T, Hall M, Aplenc R. Evaluation of Resources Used During Care of Children with High-Risk Neuroblastoma Via Merging of Cooperative Group Trial Data and Administrative Data. American Society of Clinical Oncology Annual Meeting, Chicago, June 2014.
DuBois D, Mosse y, Fox E, Reid J, Groshen S, Czarnecki S, Tsao-Wei D, Bagatell R, Maris J, Wagner L, Kudgus R, Marachelian A, Matthay K. Phase I Study of the Aurora A Kinase Inhibitor MLN8237 with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma: A Report from the New Approaches to Neuroblastoma Therapy (NANT) Consortium. Advances in Neuroblastoma Research, Cologne, April 2014.
Bagatell R, McHugh K, Naranjo A, Van Ryn C, Kirby C, Brock P, Lyons K, States LJ, Rojas Y, Miller A, Volchenbaum S, Simon T, Krug B, Sarnacki S, Minard V, Von Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J. Assessment of Primary Site Response in Children with High Risk Neuroblastoma: An International Multicenter Study. Advances in Neuroblastoma Research, Cologne, April 2014.
Hill-Kayser CE, Bagatell R, Reilly A, Womer R, Balamuth N, Both S, Lustig RA, Tochner Z. Outcomes After Proton Therapy for Pediatric Patients with Cancers of the Head and Neck Region. American Society for Radiation Oncology Annual Meeting, Atlanta, September 2013.
Thompson, RF, Levin LM, Bagatell R, Hill-Kayser CE. A Study of Dosimetry and Radiation-Induced Toxicity in the Developing Dentition of Pediatric Patients with Head and Neck Cancer. American Society for Radiation Oncology Annual Meeting, Atlanta, September 2013.
Polishchuk AL, Little A, Dubois SG, Bagatell R, Hawkins RA, Matthay KK, Hill-Kayser C, Haas-Kogan DA. Predilection for First Relapse in Previous Sites of Bony Disease in Patients with Metastatic High-Risk Neuroblastoma. American Society for Radiation Oncology Annual Meeting, Atlanta, September 2013.
37. Getz KD, Li Y, Alonzo TA, Hall M, Gerbing RB, Sung L, Huang YS, Arnold S, Seif AE, Miller TP, Bagatell R, Fisher BT, Adamson PC, Gamis A, Keren R, Aplenc R. Comparison of Inpatient Costs for Children Treated on the AAML0531 Clinical Trial: A Report from the Children’s Oncology Group. Pediatric Blood and Cancer. 2015 May 6. doi: 10.1002/pbc.25569. [Epub ahead of print]
36. Miller TP, Troxel AB, Li Y, Huang Y-S, Alonzo TA, Gerbing RB, Hall M, Torp K, Fisher BT, Bagatell R, Seif AE, Sung L, Gamis A, Rubin D, Luger S, Aplenc R. Comparison of Administrative/Billing Data to Expected Protocol-Mandated Chemotherapy Exposure in Children with Acute Myeloid Leukemia: A Report from the Children’s Oncology Group. Pediatric Blood and Cancer. 2015 Mar 11. doi: 10.1002/pbc.25475. [Epub ahead of print]
Goodman EK, Reilly AR, Fisher BT, Fitzgerald J, Li Y, Seif AE, Huang Y-S, Bagatell R, Aplenc R. Impact of weekend admission on hospital length of stay and rate of organ failure in pediatric patients with leukemia at freestanding US children’s hospitals. JAMA Pediatrics. 168 (10): 925-31, 2014.
Norris RE, Shusterman S, Gore L, Muscal JA, Macy ME, Fox E, Berkowitz N, Buchbinder A, Bagatell R. Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. Pediatric Blood and Cancer. 61(10):1792-7, 2014.
olishchuk AL, Li R, Hill-Kayser C, Little A, Hawkins RA, Hamilton J, Lau M, Tran HC, Strahlendorf C, Lemons RS, Weinberg V, Matthay KK, DuBois SG, Marcus KJ, Bagatell R, Haas-Kogan DA. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys. 89(4):839-45, 2014.
Seif AE, Walker DM, Li Y, Huang Y-S, Kavcic M, Torp K, Bagatell R, Fisher BT and Aplenc R. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients. Pediatric Blood and Cancer. Mar 26, 2014 (Epub ahead of print).
Desai AD, Kavcic M, Huang Y-S, Herbst N, Fisher BT, Seif AE, Li Y, Hennessy S, Aplenc R, Bagatell R. Establishing a High-Risk Neuroblastoma Cohort Using the Pediatric Health Information System Database. 61 (6): 1129-31, 2014.
Fisher BT, Kavcic M, Li Y, Seif AE, Bagatell R, Huang Y-S, Zaoutis T, Torp K, Leckerman KH, Aplenc R. Antifungal Prophylaxis Associated with Decreased Induction Mortality Rates and Resources Utilized in Children with New Onset Acute Myeloid Leukemia. Clinical Infectious Diseases. 58(4): 502-8, 2014.
Bagatell R, Norris RE, Ingle AM, Ahern CH, Voss S, Fox E, Little A, Weigel B, Adamson PC, Blaney SM. Phase 1 Trial of Temsirolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents and Young Adults with Relapsed or Refractory Solid Tumors: A Children’s Oncology Group Study. Pediatric Blood and Cancer. 61(5):833-9, 2014.
Alcorn KM, Deans KJ, Congeni A, Sulkowski JP, Bagatell R, Mattei P, Minneci PC. Sentinel lymph node biopsy in pediatric soft tissue sarcoma patients: utility and concordance with imaging. J Pediatr Surg. 48 (9):1903-6, 2013.
Hill-Kayser C, Tochner Z, Both S, Lustig R, Reilly A, Balamuth N, Womer R, Maris JM, Grupp S, Bagatell R. Proton Versus Photon Radiation Therapy for Patients with High-Risk Neuroblastoma: The Need for a Customized Approach. Pediatric Blood and Cancer, 60 (10): 1606-11, 2013.
Kavcic M, Fisher BT, Li Y, Seif AE, Torp K, Walker DM, Huang YS, Tasian SK, Vujkovic M, Bagatell R, Aplenc R. Induction Mortality and Resource Utilization in Children Treated for Acute Myeloid Leukemia at Free-Standing Pediatric Hospitals in the United States. Cancer 119 (10):1916-23, 2013.
Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendren A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L. A Multi-center Phase Ib Study of Oxaliplatin in Combination with Fluorouracil and Leucovorin in Pediatric Patients with Advanced Solid Tumors. Pediatric Blood and Cancer 60(2): 230-6, 2013.
Posters and Presentations
“Targeted Therapy Comes of Age for the Treatment of High-Risk Neuroblastoma” Oncology Research Conference, Texas Children’s Hospital, Baylor College of Medicine, Houston TX, March 2015.
“The Long and Winding Road Toward Development of New Drugs for Childhood Cancer” Pediatric Grand Rounds, Sinai Hospital, Baltimore MD, October 2014.
“Optimizing Care for Children with High Risk Neuroblastoma” American Society of Clinical Oncology Annual Meeting Oral Presentation Discussant, Chicago IL, June 2013.
“Care of Children with Cancer in the Era of Precision Medicine” Cutting-Edge Medicine in Every Day Practice Conference, Philadelphia PA, April 2013.
“ Pediatric Oncology Care in the Age of Precision Medicine” Hamad Medical Center, Doha, Qatar, January 2013.
“Current Therapy for Children with High-Risk Neuroblastoma” Sheikh Khalifa Hospital Medical Center, Abu Dhabi, United Arab Emirates, January 2013.
- Awards and Honors
2006-2015, Best Doctors in America
2006, Alpha Omega Alpha
2002, Vernon and Virginia Furrow Award for Excellence in Clinical Science Teaching
2001, University Animal Care Outstanding Investigator Award, University of Arizona
2000, Children’s Oncology Group Young Investigator Award
2000, University of Arizona, College of Medicine, Dean’s Physician Scientist Career Development Award
1999, Pharmacia-Upjohn Outstanding Fellow Award, Arizona Cancer Center, Tucson AZ
1996, Resident of the Year, Pima County Pediatric Society, Tucson AZ
1996, Resident Teacher of the Year Award, Department of Pediatrics, University of Arizona
1993, Hugh Thompson Award, Outstanding Medical Student in Pediatrics
1989-1993, Dean’s Scholar, University of Arizona
1987, Phi Beta Kappa
- Editorial and Academic Positions
Editorial Board, The Oncologist
Ad Hoc Reviewer
Cancer Chemotherapy and Pharmacology
Clinical Cancer Research
Journal of Clinical Oncology
Molecular Cancer Therapeutics
Pediatric Blood and Cancer
Academic and Institutional Committees
2009-present, Co-leader, Clinical Restructuring Team
2010-present, Director, Solid Tumor Service, Division of Oncology
2010-present, Proton Triage Committee Member
2009, Judge, CHOP Research Poster Day
2009-present, Oncology Website Redesign Committee
2009-present, SPECT CT Committee, Department of Radiology
2009-present, Clinical Research Quality Assurance Committee, Division of Oncology
2008-present, Pediatric Protocol Review Committee, Division of Oncology
Memberships in Professional Organizations
American Association for Cancer Research
American Society of Clinical Oncology
American Society of Pediatric Hematology/Oncology
American Academy of Pediatrics
- Awards and Honors